Biofrontera Inc. (BFRI): Price and Financial Metrics
BFRI Price/Volume Stats
| Current price | $1.67 | 52-week high | $13.42 |
| Prev. close | $1.71 | 52-week low | $0.61 |
| Day low | $1.65 | Volume | 40,700 |
| Day high | $1.82 | Avg. volume | 677,252 |
| 50-day MA | $1.29 | Dividend yield | N/A |
| 200-day MA | $4.95 | Market Cap | 8.50M |
BFRI Stock Price Chart Interactive Chart >
Biofrontera Inc. (BFRI) Company Bio
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Latest BFRI News From Around the Web
Below are the latest news stories about BIOFRONTERA INC that investors may wish to consider to help them evaluate BFRI as an investment opportunity.
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Biofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call TranscriptBiofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good day, and welcome to the Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Tirth Patel with LHA Investor Relations. […] |
Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% PlummetTo the annoyance of some shareholders, Biofrontera Inc. ( NASDAQ:BFRI ) shares are down a considerable 50% in the last... |
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business UpdateConference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023WOBURN, MA / ACCESSWIRE / November 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic ... |
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should KnowBiofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
BFRI Price Returns
| 1-mo | 31.50% |
| 3-mo | 1.83% |
| 6-mo | -58.66% |
| 1-year | -86.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.71% |
| 2023 | -84.89% |
| 2022 | -87.81% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...